Expert InterviewAZN
Slingshot members are talking to an expert! The topic is:
Discussing the AstraZenaca's B7-H4–targeting topoisomerase 1 inhibitor antibody-drug conjugate, puxitatug samrotecan (AZD8205), and the results from the phase 1/2a BLUESTAR study in endometrial cancer presented at the 2025 SGO Meeting.
Executed on:Apr 3, 2025 10:00 AM EDT
Call Duration:30 minutes
Expert Profile
ExpertBlinded Expert
Institution: Albert Einstein College of Medicine
- Professor of Clinical Obstetrics & Gynecology and Women's Health in the department of Gynecological Oncology.
- Cares for 100 patients with endometrial cancer per year
- Research interests include improving palliative medicine for women with gynecological cancers and leading over 20 industry sponsored, cooperative group, and investigator initiated behavioral and chemotherapeutic trials as institutional principle investigator.
Interview Goal
On this call we will be discussing the potential of puxitatug samrotecan (AZD8205), a B7-H4–targeting topoisomerase 1 inhibitor antibody-drug conjugate (ADC) and the results from the phase 1/2a BLUESTAR study (NCT05276548) in endometrial cancer presented at the 2025 SGO Annual Meeting on Women’s Cancer.